Issues
-
Cover Image
Cover Image
Myostatin gene inactivation drastically reduces the development of polyposis in ApcMin/+ mouse. The ApcMin/+ mouse has a mutation in the adenomatous polyposis coli (Apc) tumor suppressor gene, which is responsible for the development of colorectal cancer and cachexia. Myostatin is a master negative regulator of skeletal muscle mass. It was found that inactivation of the myostatin gene on the ApcMin/+ genetic background, a condition that completely prevents cancer cachexia, strikingly reduced the number and size of intestinal polyps. For details see article by Gallot and colleagues on page 7344. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Perspectives
Priority Reports
AKT1 and MYC Induce Distinctive Metabolic Fingerprints in Human Prostate Cancer
Clinical Studies
Chemoradiotherapy-Induced Upregulation of PD-1 Antagonizes Immunity to HPV-Related Oropharyngeal Cancer
Integrated Systems and Technologies
Microenvironment and Immunology
Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma
Molecular and Cellular Pathobiology
H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis
Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in Cancer
Combined Genome and Transcriptome Analysis of Single Disseminated Cancer Cells from Bone Marrow of Prostate Cancer Patients Reveals Unexpected Transcriptomes
Differentiation and Loss of Malignant Character of Spontaneous Pulmonary Metastases in Patient-Derived Breast Cancer Models
Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma
Prevention and Epidemiology
Plasma Choline Metabolites and Colorectal Cancer Risk in the Women's Health Initiative Observational Study
Therapeutics, Targets, and Chemical Biology
Tumor and Stem Cell Biology
Downregulated miR329 and miR410 Promote the Proliferation and Invasion of Oral Squamous Cell Carcinoma by Targeting Wnt-7b
Letter to the Editor
Acknowledgment to Reviewers
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.